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Fbx4 is a speciﬁc substrate recognition component of SCF ubiquitin ligases that catalyzes the ubiquitina-
tion and subsequent degradation of cyclin D1 and Trx1. Two isoforms of human Fbx4 protein, the full
length Fbx4a and the C-terminal truncated Fbx4b have been identiﬁed, but their functions remain elu-
sive. In this study, we demonstrated that the mRNA level of Fbx4 was signiﬁcantly lower in hepatocellular
carcinoma tissues than that in the corresponding non-tumor tissues. More importantly, we identiﬁed
three novel splicing variants of Fbx4: Fbx4c (missing 168–245nt of exon1), Fbx4d (missing exon6) and
a N-terminal reading frame shift variant (missing exon2). Using cloning sequencing and RT-PCR, we dem-
onstrated these novel splice variants are muchmore abundant in human cancer tissues and cell lines than
that in normal tissues. When expressed in Sk-Hep1 and NIH3T3 cell lines, Fbx4b, Fbx4c and Fbx4d could
promote cell proliferation and migration in vitro. Concordantly, these isoforms could disrupt cyclin D1
degradation and therefore increase cyclin D1 expression. Moreover, unlike the full-length isoform Fbx4a
that mainly exists in cytoplasm, Fbx4b, Fbx4c, and Fbx4d locate in both cytoplasm and nucleus. Since
cyclin D1 degradation takes place in cytoplasm, the nuclear distribution of these Fbx4 isoforms may
not be involved in the down-regulation of cytoplasmic cyclin D1. These results deﬁne the impact of alter-
native splicing on Fbx4 function, and suggest that the attenuated cyclin D1 degradation by these novel
Fbx4 isoforms provides a new insight for aberrant cyclin D1 expression in human cancers.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction Substrate speciﬁcity is decided by the F-box protein subunit ofUbiquitin (Ub)-mediated proteolysis is an important means of
regulating gene expression and has a pivotal role in the control
of various cellular processes [1]. Ubiquitination is catalyzed via a
triple-enzyme cascade including an E1 (Ub-activating enzyme),
E2 (Ub-conjugating enzyme), and E3 (Ub ligase). Once ubiquitinat-
ed, proteins are rapidly hydrolyzed by the 26S proteasome. The
substrate speciﬁcity is largely conferred by E3 ligases, and the
interaction between substrates and E3 is crucial for the regulation
of Ub-mediated protein turnover [2].
Skp-cullin-F-box (SCF) Ub ligases are multi-subunit complexes
that mediate speciﬁc ubiquitination of distinct substrates [3].the complex. Recently, the Ub ligase SCFFbx4 has been identiﬁed
as a new E3 responsible for the ubiquitination and subsequent deg-
radation of the cell cycle regulator cyclin D1 and telomeric DNA-
binding protein Pin2 (also known as Trf1) [4,5]. Fbx4 belongs to
the FBXO subfamily of F-box proteins in which the substrate-bind-
ing motif has not been identiﬁed yet [6]. Structurally, Fbx4 has sev-
eral identiﬁed domains essential for its function in SCF complex: N-
terminal dimerization domain (D domain), F-box domain, linker
domain and C-terminal substrate-binding domain (G domain) [6–
9]. Structural and biochemical analyses have revealed that the
interaction between linker domain and G domain is crucial for
the head-to-tail dimerization conﬁguration of Fbx4, which is re-
quired for substrate binding and ubiquitin transfer [9].
Fbx4 recognizes its two known substrates cyclin D1 and Pin2 in
two very different manners. Fbx4-mediated ubiquitination of cy-
clin D1 depends on its phosphorylation at Thr-286 residue, as well
as an interaction with aB-crystallin, a small heat-shock protein,
whereas that of Pin2 does not require phosphorylation [4,5,10].
Inhibition of Fbx4 activity results in accumulation of nuclear cyclin
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account for overexpression of cyclin D1 in human cancers [5,11],
and mutations in the Fbx4 subunit of SCFFbx4 were found to be
associated with human primary esophageal carcinoma [12,13].
Therefore, the regulation of SCFFbx4 activity is considered to be very
important to sustain cyclin D1 level in normal cells, and impair-
ment of SCFFbx4 function is a critical mechanism underlying cyclin
D1 overexpression in human cancers.
To date, two Fbx4 isoforms (named Fbx4a and Fbx4b in this pa-
per) created by alternative splicing have been identiﬁed, but the
roles these two isoforms play in SCFFbx4 activity remain incom-
pletely understood. Although the alternative splicing has been as-
signed as a regulatory mechanism for F-box protein [14], the
speciﬁc differences of Fbx4 splicing proﬁles in cancer tissues re-
main elusive. In this study, we identiﬁed the presence of additional
oncogenic splicing variants of Fbx4 in human tissues and these no-
vel Fbx4 splicing variants are much more abundant in tumor tis-
sues and cell lines than that in normal tissues. The attenuated
cyclin D1 degradation by these novel Fbx4 isoforms in vitro pro-
vides a new insight for aberrant cyclin D1 expression and tumor
development in human cancer.2. Materials and methods
2.1. Cell lines and tissues
Human liver cancer cell lines SNU182, SNU449, HepG2, SK-
Hep1 and mouse embryo ﬁbroblast cell line NIH3T3 were pur-
chased from ATCC (American Type Culture Collection; Manassas,
VA, USA). The esophagus carcinoma cell lines KYSE450, KYSE510,
SEG-1, BIC-1 and gastric cancer cell line NUGC3 were gifts from
Professor Mingzhou Guo (Chinese PLA General Hospital).
A total of 40 pairs of HCC tissues and non-tumor tissues were
provided by the Afﬁliated Oncology Hospital of Zhengzhou Univer-
sity. Both tumor samples and non-tumor samples were conﬁrmed
histologically. The usage of human samples in this study has been
carried out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) and approved by
the Ethics Committee of Peking University Health Science Center.
2.2. Reverse transcriptase polymerase chain reaction (RT-PCR)
Quantitative real-time RT-PCR (qRT-PCR) was carried out using
SYBR Green on a LightCycler 480IIreal-time PCR detection system
(Roche, Germany) according to the manufacturer’s instruction. To
quantify novel Fbx4 isoforms, semi-quantitative PCR was per-
formed with primers speciﬁc to each isoform, and the products
were analyzed on 2% agarose gel. The primers used for RT-PCR
are summarized in Table S1.
2.3. Clone-sequencing of Fbx4 mRNA composition
To clone Fbx4 mRNA, PCR reactions were performed with prim-
ers CDS1-F/R and CDS2-F/R (Table S1) by using cDNA from normal
tissues and tumor cell lines, respectively. PCR products were puri-
ﬁed and cloned into TA vector and transformed into Escherichia coli
DH5a competent cells. Cell clone was randomly picked up and
sequenced.
2.4. Plasmid construction
To construct vectors expressing Fbx4 isoforms, cDNA fragments
from normal liver tissues were prepared by RT-PCR with speciﬁc
primers (Table S1). The cDNA of Fbx4 isoforms was then cloned
into pcDNA™3.1/Myc-His () vector (Invitrogen, Carlsbad,California). All expressing vectors were veriﬁed by DNA sequencing
and Western blot assay.
2.5. Colony formation assay
Colony formation assay were performed using a soft agar kit
(GenMed Scientiﬁcs, Inc., Arlington, USA) in 6-well plates accord-
ing to the manufacturer’s instructions. Colonies were photo-
graphed and counted under a microscope with a digital camera.
2.6. Transwell assay
The transwell system was used to explore cell’s migration. A to-
tal of 7500 cells suspended with 150 lL of FBS-free medium were
added into the inside compartment of the transwell insert. After
48-h incubation, the migrated cells were stained with 0.1% crystal
violet and quantiﬁed under a light microscope, with at least three
individual ﬁelds per insert.
2.7. Immunoﬂuorescence assays
Cells were permeabilized with Methanol:Acetone (1:1), washed
with PBS and incubated in primary anti-Myc antibody for 2 h. After
washing and application of the secondary FITC-conjugated second-
ary antibody, slides were stained using Hoechst 33258 dye and
analyzed by ﬂuorescence microscopy (LEICA).
2.8. Subcellular fractionation analysis
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientiﬁc, Pittsburgh, PA) were used to get cytoplasmic extract and
nuclear extract, respectively, according to the manufacturer’s
recommendation.
2.9. Immunoprecipitation (IP) and Western blot assays
For IP assay, cells were lysed with IP buffer. The cell lysates
were incubated with the primary antibody and then immunocom-
plexes were bound to protein-G Sepharose 4B (Pharmacia, Swe-
den). After extensive washing, the precipitates were analyzed by
Western blot. Western blot analysis was performed as described
[13]. The antibodies used for IP and Western blot analysis were
listed in Table S2.
2.10. Statistical analysis
For statistical analyses, the difference between two groups was
analyzed by 2-tailed Student t test using GraphPad Prism software.
In all cases, a P value of less than 0.05 was considered signiﬁcant.3. Results
3.1. Fbx4 is down-regulated in HCC tissues
To examine whether Fbx4 is down-regulated in HCC tissues, we
performed qRT-PCR to measure Fbx4 mRNA level in 40 pairs of
HCC tumor and adjacent non-tumor tissues. The result showed
that Fbx4 mRNA level in tumor tissues was signiﬁcantly lower than
that in adjacent non-tumor tissues (P = 0.0238) (Fig. 1A). To further
conﬁrm the reduced expression of Fbx4 in HCC, 9 pairs of HCC tis-
sues were used for Western blot assay to analyze Fbx4 protein le-
vel. Consistent with the lower Fbx4 mRNA level, lower Fbx4
protein level was detected in 7 of 9 HCC tumor tissues, as com-
pared to their matched non-tumor tissues (Fig. 1B).
Fig. 1. Fbx4 is down-regulated in HCC. (A) Fbx4 mRNA expression was analyzed in 40 pairs of HCC and adjacent non-tumor tissues by real-time qRT-PCR using GAPDH for
normalization. Horizontal bars represent median expression levels. Signiﬁcant differences were determined using Student’s t tests; (B) Western blot assay was used to detect
the protein level of Fbx4 in 9 pairs of HCC and adjacent non-tumor samples.
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To date, only two Fbx4 splicing variants created by alternative
splicing are identiﬁed. Variant 1, the original transcript identiﬁed,
contains 7 exons and encodes an isoform (Fbx4a) of 387 amino
acids. Variant 2 contains an altered C-terminus, characterized by
7 amino acids encoded by a read through into intron 5, with the en-
tire exon 6-encoded sequence being replaced. To further explore
the complexity of Fbx4 splicing variation, we designed primers
crossing the entire coding sequence of Fbx4 variant 1 and per-
formed RT-PCR to assess Fbx4 mRNA pools in 4 liver cancer cell
lines (SNU182, SNU449, HepG2, SK-Hep1) and disease-free normal
liver tissues. Interestingly, the resolution of PCR products on aga-
rose gel revealed that, besides the expected full-length Fbx4 variant
1, the primers of Fbx4 also produced several other DNA bands,
which were smaller than expected size (Fig. 2A). Similar DNA bands
of Fbx4 PCR productswere also found in 4 esophagus carcinoma cell
lines (KYSE450, KYSE510, SEG-1, BIC-1) and 1 gastric cancer cell line
(NUGC3). To identify these unknown DNA fragments, the PCR prod-
ucts were then cloned into T-vector and randomly picked up for
sequencing. These smaller bands were proved to be novel alterna-
tive splicing variants of Fbx4 gene (Fig. 2B), and were named Fbx4
variant 3, Fbx4 variant 4 and Fbx4 variant 5. All variants were deriv-
atives of the full-length variant 1 (Fig. 2C). The variant 3 has a 168–
245nt deletion of exon1 and produces an isoform of 351 amino
acids (named Fbx4c).The variant 4 has a loss of the whole exon 6
and produces an isoform similar to Fbx4 isoform 2 (named
Fbx4d).The variant 5 lacks the whole exon 2 and leads to a reading
frame shift, which makes it infertile to translate into protein. These
data suggest that more isoforms of Fbx4 exist than previously iden-
tiﬁed via the alternative splicing.3.3. Tumor tissues express more Fbx4 variants
To test whether tumor cells have a more complex splicing var-
iation of Fbx4 than normal cells, clone-sequencing analysis was
conducted in normal liver tissue, normal esophagus tissue and 3
tumor cell lines: HepG2, BIC-1 and NUGC3. A total of 30 clones
from each specimen were randomly picked up and sequenced.
Our data showed that compared to the normal tissues, cancer cell
lines indeed accommodated less wild-type Fbx4 variant 1
(P < 0.0001). In NUGC3 cells, even no Fbx4 variant 1 clone was de-
tected (Table 1). When we searched human EST database to exam-
ine the presence of these variants, we could ﬁnd the sequences of
Fbx4 variant 4 and 5, but not that of variant 3. Interestingly, the no-
vel splicing variants of Fbx4 existed in all three cancer cell lines as
well as in the two normal human tissues, but with abundant differ-
ences. Among the 3 novel Fbx4 variants, the non-protein-coding
variant 5 was the most abundant splicing variant in tumor cells
(46.7 – 76.7% of all transcripts tested), much higher than that in
normal tissues. Although there are no big differences in fractionof variant 3 and 4 between the normal human tissues and tumor
cell lines, it is worthwhile to note that in NUGC3 cells, due to lack
of the full length Fbx4 variant 1, Fbx4 variant 3 and variant 4 pres-
ent as the only protein coding Fbx4 transcription variants. Semi-
quantitative RT-PCR analysis of 7 pairs of HCC tumor tissues and
the adjacent non-tumor tissues further conﬁrmed that some HCC
tumor tissues indeed expressed more Fbx4 variants (Fig. 2D).
3.4. Fbx4 isoforms exhibit oncogene functions
To directly address the potential role of Fbx4 isoforms, SK-Hep1
and NIH3T3 cells were transfected with either empty vector or C-
terminal Myc-tagged Fbx4 expressing vector. Malignant character-
istics of cells expressing Fbx4c, Fbx4d and Fbx4b were veriﬁed and
compared with control cells in terms of their clonogenicity, wound
healing ability and migration ability. As shown in Fig. 3, contrary to
Fbx4a, whose overexpression could decrease both size and number
of colonies formed by transfected cells, overexpression of Fbx4c,
Fbx4d and Fbx4b in SK-Hep1 and NIH3T3 cells facilitated cell
growth in soft agar, a characteristic of neoplastic transformation
(P < 0.05 from control of Fbx4a, Fig. 3A). In addition, ectopic
expression of Fbx4c, Fbx4d and Fbx4b in both cells remarkably en-
hanced cell migration ability as determined by transwell assay,
which showed that migrated cells are dramatically increased in
these isoforms transfected cells (P < 0.05 or P < 0.01 from control
of Fbx4a, Fig. 3B). The promoting effect of these isoforms on cell
migration was further conﬁrmed by wound-healing assay
(P < 0.05 or P < 0.01 from control of Fbx4a, Fig. 3C). Taken together,
these data suggest that Fbx4c, Fbx4d and Fbx4b represent onco-
genic potential in this context.
3.5. Different subcellular localization of Fbx4 isoforms
It has been reported that different isoforms of F-box protein may
have different subcellular distribution with altered functions
[15,16]. To test whether these novel Fbx4 isoforms exhibit different
subcellular localizations, Myc-tagged Fbx4 isoforms were transfec-
ted into NIH3T3 cells. Indirect immunoﬂuorescence staining
showed that Fbx4a tends to bemainly localized in cytoplasm, while
Fbx4c, Fbx4d and Fbx4b existed in both cytoplasm and nucleus
(Fig. 4A). The subcellular localizations of these isoformswere further
conﬁrmed byWestern blot analysis (Fig. 4B). The different subcellu-
lar localizations of these Fbx4 isoforms suggest that they may have
different biological roles in the regulation of substrate degradation.
3.6. Differential abilities of Fbx4 isoforms on the regulation of cyclin D1
degradation
Based on the understanding of Fbx4 protein structure (Fig. 2C),
Fbx4c lacks parts of both D domain and F-box domain; Fbx4d and
Fbx4b both lack part of G domain. We postulated that these novel
Fig. 2. Identiﬁcation of novel Fbx4 splicing variants. (A) The novel Fbx4 splicing variants were identiﬁed by RT-PCR with primers crossing the entire CDS of Fbx4. (B) The
sequencing results of the novel Fbx4 variants are presented in the sense direction. (C) Schematic diagrams of the identiﬁed Fbx4 variants. (D) Expression of Fbx4 variants in 7
pairs of HCC and adjacent non-tumor samples, and 3 normal liver tissues detected by using semi-quantitative RT-PCR. , expression in tumor tissue is higher than that in
corresponding non-tumor tissue.
Table 1
Distribution of Fbx4 variants in normal human tissues and cancer cell lines.
Variant Normal liver
tissue
Normal esophagus
tissue
HepG2 BIC-1 NUGC3
Fbx4 1 20 (66.7%) 18 (60.0%) 10 (33.4%) 11 (36.7%) 0
Fbx4 3 1 (3.3%) 0 1 (3.3%) 1 (3.3%) 6 (20.0%)
Fbx4 4 6 (20.0%) 5 (16.7%) 4 (13.3%) 4 (13.3%) 1 (3.3%)
Fbx4 5 3 (10.0%) 7 (23.3%) 15 (50.0%) 14 (46.7%) 23 (76.7%)
Total 30 30 30 30 30
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increase the accumulation of downstream substrates. The inﬂu-
ence of these Fbx4 isoforms on the level of endogenous cyclin D1
and Pin2/Trf1, two known Fbx4 substrates, were then analyzed
by Western blot assay. As shown in Fig. 4C, ectopic expression of
Fbx4c, Fbx4d and Fbx4b all signiﬁcantly enhanced the expression
of cyclin D1 protein, while Pin2/Trf1 was barely affected.Immunoprecipitation analysis revealed that Fbx4c, Fbx4d and
Fbx4b were still capable to bind to cyclin D1, but not as powerful
as Fbx4a. (Fig. 4D). Consistent with the weak ability of these iso-
forms to bind to cyclin D1, turnover assay demonstrated that over-
expression of Fbx4c, Fbx4d or Fbx4b signiﬁcantly extended the
half-life of endogenous cyclin D1 protein (Fig. 4E), indicating that
these isoforms appear to up-regulate cyclin D1 expression by
reducing its degradation.4. Discussion
Abnormal cyclin D1 degradation has been implicated as a caus-
ative factor leading to its overexpression in human tumors [5,17];
however the underlying mechanisms remain ambiguous. Aberrant
proteolytic degradation was initially thought as a result of the cy-
clin D1 Thr286 residue mutation or deletion, which renders cyclin
D1 protein more stable [17,18]. However, this cancer-derived cy-
clin D1 mutation is rare in cancer, implying the involvement of
Fig. 3. Fbx4 isoforms exhibit oncogene activities. (A) Representative colony formation and corresponding histogram of SK-Hep1 and NIH3T3 cells transfected with Fbx4
isoforms. (B) Representative transwell migration and corresponding histogram of SK-Hep1 and NIH3T3 cells transfected with Fbx4 isoforms. (C) Representative scratch-
wound assay and corresponding histogram of SK-Hep1 and NIH3T3 cells transfected with Fbx4 isoforms. Data are presented as mean ± SD from at least 3 independent
experiments. The signiﬁcance was calculated with two-tailed Student t-test. ⁄P < 0.05 and ⁄⁄P < 0.01 from control of Fbx4a.
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quently found in various human malignancies. SCFFbx4/aB-crystallin
is a recently identiﬁed E3 ligase complex that directs ubiquitin-
mediated proteolysis of cyclin D1 [8]. Herein, we identiﬁed several
previously unknown Fbx4 isoforms produced by alternative splic-
ing. These isoforms showed less capability for cyclin D1 binding
and degradation. Importantly, we demonstrated that these isforms
had obvious oncogenic properties of promoting tumor cell growth
and metastasis. Therefore, alternative splicing of Fbx4 may add an-
other level of complexity to the regulation of cyclin D1 in tumor
development.
Alternative splicing is a major regulatory mechanism to control
gene usage and increase coding capacity, and deregulation of this
process is known to underlie the pathogenesis of diverse human
diseases including tumor formation [19]. Alternative splicing has
been assigned as a regulatory mechanism for the production of
F-box proteins such as Skp2, Fbw7 andb-TrCP, which are responsi-
ble for the regulation of proteins that control diverse cellular sig-
naling events [14,15,20]. In this study, we are the ﬁrst to provide
evidence that not only does Fbx4 expression decrease in HCC tis-
sues, but also Fbx4b, Fbx4c and Fbx4d are the dominant isoforms
expressed in cancer. The changes of alternative splicing patternof Fbx4 in cancer suggest that these new splice-variants may be
putative oncogenes involved in carcinogenesis. This notion is fur-
ther supported by data from the functional characterization
in vitro, which showed an increased clonogenicity, wound healing
ability and migration ability in NIH3T3 and Sk-Hep1 cells over-
expressing these isoforms.
The integrity of Fbx4 domains is indispensable for its dimeriza-
tion and subsequent activation of Fbx4 in SCF complex and Fbx4-
mediated substrate degradation [14,21,22]. The N-terminal con-
served D domain (residue1-57) of Fbx4 protein is important for
interaction with Cul1 and also for Fbx4 dimerization and ubiquiti-
nation activity. In addition, a loop connecting the linker domain
(residue 105–162) to the C-terminal G domain (residue 163–387)
is crucial for dimerization, and the head-to-tail dimerization con-
ﬁguration of Fbx4 protein likely plays a role in stabilizing optimal
orientation of the F-box domain (residue 58–104) and G domain
and thus exposing the substrate-binding site in the G domain [9].
Our sequencing analyses demonstrate that Fbx4b is divergent from
Fbx4a in the C-terminal and has an incomplete substrate-binding
domain; Fbx4c suffers a 168–245nt deletion of exon1 and pro-
duces a protein lacking parts of both D domain and F-box domain;
Fbx4d is similar to Fbx4b and lacks part of G domain. Thus, it is
Fig. 4. The Fbx4 isoforms have different subcellular localization and reduced activity toward cyclin D1degradation. (A) Immunoﬂuorescence was performed using NIH3T3
cells transfected with the indicated Fbx4 isoforms. (B) Nuclear fraction and Fbx4 immunoblot of NIH3T3 cells transfected with the indicated Fbx4 isoforms. (C) Endogenous
cyclin D1and Pin2 were detected by Western blot assay. (D) The ability of Fbx4 binding to cyclin D1 in SK-Hep1 and NIH 3T3 cells was detected by immunoprecipitation
analysis. The samples labeled ‘‘input’’ were typically 10% of the samples employed in binding experiments. (E) Representative immunoblot of cyclin D1 and corresponding
histogram in SK-Hep1 and NIH3T3 cells incubated with Cycloheximide (CHX, 50 lg/mL). Data are presented as mean ± SD from at least 3 independent experiments. ⁄P < 0.05
and ⁄⁄P < 0.01 from control of Fbx4a.
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to failure of Fbx4 dimerization, substrate binding, and inactivation
of the SCFFbx4 ubiquitin ligase. In consist with this notion, ectopic
expression of Fbx4b, Fbx4c and Fbx4d in NIH3T3 and Sk-Hep1 cells
can disrupt endogenous cyclin D1 turnover and increase cyclin D1
expression at protein level. However, no signiﬁcant increase of
Pin2/Trf1 was observed by overexpression of Fbx4b, Fbx4c or
Fbx4d, which further support the notion that Fbx4 recognizes its
two substrates, Pin2/Trf1 and cyclin D1, in two very different man-
ners [4,5,10]. Since cyclin D1 overexpression has been recognized
as one of the most common mechanisms contributing to tumori-
genesis in a variety of human malignancies, the up-regulation of
cyclin D1 induced by these Fbx4 isoforms may at least in part con-
tribute to their oncongenic roles. However, additional studies arerequired to determine the molecular details of these Fbx4 isoforms
on the cyclin D1 degradation.
Recent studies have provided evidences that different isoforms
of F-box protein may have different subcellular distribution with
altered functions [15,16]. We found that Fbx4a is mainly localized
in cytoplasm, while Fbx4b, Fbx4c and Fbx4d existed in both cyto-
plasm and nucleus. Phosphorylation of cyclin D1 at T286 triggers
CRM1-dependent nuclear export of protein to the cytoplasm,
where it is recognized and degraded by SCFFbx4/aB-crystallin ligase.
Since the degradation of cyclin D1 takes place in cytoplasm, the nu-
clear distribution of Fbx4b, Fbx4c or Fbx4d may be negatively in-
volved in the down-regulation of cytoplasmic cyclin D1.
Therefore, in addition to the dimerization disturbing hypothesis,
the different subcellular distribution characteristic of these Fbx4
164 X. Chu et al. / Biochemical and Biophysical Research Communications 447 (2014) 158–164isoforms may provide another explanation for their abated capabil-
ity for cyclin D1 degradation. Further study should investigate the
mechanism of Fbx4 isoform-speciﬁc localization, which will help
to establish the signiﬁcance of these isoforms in the regulation of
substrates degradation.
In conclusion, we identiﬁed and characterized novel Fbx4 iso-
forms, which are produced by alternative splicing of Fbx4 pre-
mRNA. These novel isoforms attenuate Fbx4-dependent cyclin D1
degradation and display obvious oncogenic properties. Our study,
together with those of other groups, broadens current understand-
ing of F-box protein regulation and emphasizes the importance of
alternative splicing proﬁling in cancer. Future studies are required
to ﬁgure out why abnormal splicing pattern of Fbx4 happens in
cancer. Exploration of functions and mechanisms of these isoforms
may be helpful to develop potential biomarkers and drugs for the
prognosis and therapy of cancer.
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